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Abstract
Although cellular senescence has emerged as a novel therapeutic concept in cancer, its underlying mechanisms
remain unclear. High mobility group box 1 (HMGB1) and stimulator of interferon genes (STING) are involved in
senescence. However, their interactions in senescence have not been reported. Therefore, in this study, we
investigated the relationships between HMGB1 and STING in senescence in cancer and other cells. In mouse
melanoma cells and several other cell lines, doxorubicin treatment induced senescence in an HMGB1-dependent
manner. These responses were mediated by STING, and this function of STING was negatively regulated by the E3
ligase tripartite motif protein 30α (TRIM30α). We also found that HMGB1 bound to the TRIM30α promoter and then
suppressed its expression by inhibiting its transcription, which enhanced STING-induced senescence. This mechanism
was further mediated by signal transducer and activator of transcription 6 (STAT6) and p21. Overall, our findings
demonstrated that HMGB1 orchestrated STING-STAT6-p21-mediated senescence by regulating TRIM30α as an
alternative anticancer mechanism.
Introduction
Senescence is characterized by permanent cell cycle arrest
and can be induced in multiple primary cell types following
DNA damage, such as global reorganization and degenera-
tion of chromatin, as is observed in various human diseases,
including cancer and aging1. Senescent cells show the
activity of senescence-associated β-galactosidase (SA-
β-GAL); expression of tumor suppressors and cell cycle
inhibitors, such as retinoblastoma protein, p53, p16, p27,
and p21; and lack of proliferative markers. Moreover, these
cells typically also show expression of DNA damage mar-
kers; nuclear foci of constitutive heterochromatin, which are
marked with γ-H2AX and H3K9 trimethylation; and
abundant secretion of signaling molecules, such as inter-
leukin (IL)-6 and IL-82,3.
Loss of nuclear lamin B1 protein, another senescence
marker, disrupts the integrity of the nuclear envelope.
Chromatin fragments from the nuclear membrane bleb
out to the cytoplasm and become cytoplasmic chromatin
fragments (CCFs)4. The cytosolic DNA sensor cyclic
GMP-AMP synthase (cGAS) then recognizes CCFs and
generates cytosolic GMP-AMP, which activates the sti-
mulator of interferon genes (STING)5. The cGAS/STING
pathway is crucial to various cancer therapies, including
chemotherapy, radiation therapy, and immunotherapy,
and is also linked to inflammation and senescence. In a
mouse model, significantly fewer gray hairs were observed
in STING-null mice after IR than in control mice4–6.
Furthermore, the responses of cancer cells to stresses are
varied, and cancer therapy has been shown to induce
senescence and activate the cGAS/STING pathway7.
As a member of the highly conserved nonhistone DNA-
binding high-mobility group (HMG) protein family, HMG
box 1 (HMGB1) protein shows rapid electrophoretic
mobility8 and is located in the nuclei in most cells.
HMGB1 has roles as a DNA chaperone, functioning to
maintain nuclear homeostasis, and a danger-associated
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molecular pattern molecule, acting alone or with endo-
genous or exogenous pathogen-associated molecular
pattern molecules to induce inflammation9–12.
Although HMGB1 has been shown to have important
roles in cancer, the results of various studies have been
contradictory. For example, in some studies, HMGB1 has
been shown to promote cancer development and che-
motherapy resistance; however, in other studies, HMGB1
exhibits tumor-suppressive activities13. HMGB1 is also
associated with senescence14–17, although its role in
cGAS/STING-dependent senescence in cancer cells has
not been determined.
Therefore, in this study, we evaluated the role of
HMGB1 and its relationship with the STING pathway in
genotoxic stress-induced senescence in cancer cells. Our
results provide insights into the function of HMGB1 in
STING-dependent senescence, which could be applicable
to cancer prevention.
Materials and methods
Cell culture, transfection, and reagents
B16 and B16-F10 mouse melanoma cells, mouse
embryonic fibroblasts (MEFs), J774 mouse macrophages,
and HEK293T cells were cultured in Dulbecco’s modified
Eagle’s medium. The medium was supplemented with
10% fetal bovine serum (Life Technologies, Waltham,
MA, USA) and 1% penicillin–streptomycin (Life Tech-
nologies). The Myc-tagged HMGB1 gene was inserted
into the pCMV plasmid for mammalian cell expression.
The E3 ligase tripartite motif protein 30α (TRIM30α)
promoter was inserted into the pGL3 Luciferase Reporter
vector (Promega, Madison, WI, USA). STING and
TRIM30α plasmids were purchased from Addgene
(Watertown, MA, USA). Plasmid and siRNA transfections
were carried out using FuGene HD reagent (Promega)
and RNAiMAX (Invitrogen, Carlsbad, CA, USA) respec-
tively, as recommended by the manufacturers.
Anti-HMGB1 (cat. no. ab79823), anti-TRIM30α (cat.
no. ab76953), and anti-γ-H2AX (cat. no. ab11174) anti-
bodies were obtained from Abcam (Cambridge, MA,
USA), and anti-p21 (cat. no. 556431) and anti-p27 (cat.
no. 610242) antibodies were purchased from BD Bios-
ciences (Franklin Lakes, NJ, USA). Anti-p53 antibodies
(DO-7; cat. no. SC-47698) and horseradish peroxidase-
conjugated anti-mouse and anti-rabbit antibodies were
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). Antibodies targeting STING (cat. no. 13647),
phospho-signal transducer and activator of transcription 6
(STAT6; cat. no. 56554), phospho-interferon regulatory
factor (IRF) 3 (cat. no. 4947), tri-H3K9 (cat. no. 13969),
and β-actin (cat. no. 4967S) and secondary antibodies for
immunofluorescence were obtained from Cell Signaling
Technologies, Inc. (Danvers, MA, USA). siRNA duplexes
against human and mouse HMGB1, TRIM30α, STING,
STAT6, and p21 and nonspecific control siRNA were
purchased from Bioneer Inc. (Daejeon, Korea). Doxor-
ubicin (Dox) was obtained from Calbiochem (San Diego,
CA, USA). Actinomycin D, cycloheximide, MG132, and
hydrogen peroxide (H2O2) were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Cell morphology analysis and SA-β-GAL staining
Morphological changes in cells were photographed
using an inverted phase-contrast microscope (Olympus,
Tokyo, Japan). SA-β-GAL staining was performed as
previously described18. Morphological examinations were
performed 3 days after each treatment unless otherwise
indicated.
Western blot analysis
Cells were collected and lysed in radio-
immunoprecipitation assay buffer containing protease
inhibitor cocktail (GenDEPOT, TX, USA). The lysed cells
were sonicated and incubated on ice for 30 min. The
lysates were centrifuged, and protein concentrations in
the cleared lysates were quantified using bicinchoninic
acid protein assay reagents (Pierce). Equal amounts of
total protein were separated by sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis. After the
transfer of proteins to nitrocellulose membranes, the
membranes were blocked with 5% (w/v) nonfat dry milk
in 1× phosphate-buffered saline (PBS) overnight at 4 °C.
Proteins were detected with specific antibodies.
Antibody–antigen complexes were detected using horse-
radish peroxidase-conjugated secondary antibodies and
visualized using a standard chemiluminescence method
performed according to the manufacturer’s instructions.
Quantitative real-time PCR (qRT-PCR) analysis
RNA was isolated with an RNA extraction kit (iNtRON
Biotechnology DR Inc., Daejeon, Korea) and subjected to
reverse transcription. qRT-PCR was performed using
Power SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA) with specific primers on a Step One
Plus Real-Time PCR System (Applied Biosystems). The
relative expression levels of p21, IL-6, and IL-8 mRNA
were calculated after normalizing the Ct values to that for
β-actin expression in the same sample, using the ΔΔCt
method.
Chromatin immunoprecipitation (ChIP) analysis
To examine the presence of HMGB1-binding sites
within the TRIM30α promoter region, we performed
chromatin immunoprecipitation analysis. To do this, a
reporter plasmid was constructed with the TRIM30α
promoter region sequence, which corresponds to
GRCm38:7: 104464459:104466001 by using the following
primers: sense: TTTGCTAGCTTTTTTCAGCTTTCTT
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GGTATCCAGA, antisense: TTTAAGCTTAGGAGCCA
CCACACCTGATTTT. Cells were transfected with the
constructed plasmid and grown to 90% confluence in two
confluent 150-cm2 dishes per sample, collected, washed
with PBS, and then resuspended with PBS. Next, cells
were crosslinked with 0.75% formaldehyde at 25 °C for
10min, and glycine was added to a final concentration of
125mM. Cells were then incubated at room temperature
for 5 min with gentle shaking. Samples were centrifuged,
washed with PBS, resuspended in lysis buffer (1% SDS,
10 mM ethylenediaminetetraacetic acid, 50 mM Tris-HCl
[pH 8.1]), and sonicated three times for 15 s each at the
maximum setting. Supernatants were then recovered by
centrifugation at 12,000 rpm for 10min at 4 °C, diluted
with dilution buffer (0.5% Triton X-100, 2 mM ethylene-
diaminetetraacetic acid, 100mM NaCI, 20 mM Tris-HCl
[pH 8.1]). Next, a 50 μL sample for input was taken, and
purified DNA was used to calculate the DNA con-
centration. An amount of chromatin equivalent to
approximately 25 μg DNA was used for each IP, and 2 μg
of the antibody with 20 μL protein G beads (of 50% slurry)
was combined and incubated overnight. After washing
three times, complexes were eluted by adding 250 μL
elution buffer (1% SDS/0.1M NaHCO3) to pelleted beads
for reverse cross-linking and centrifuged at 14,000 rpm for
3 min. Pelleted DNA from the supernatants was purified
using a spin column, and PCR was then carried out with
target-specific primers.
Luciferase reporter assay
Cells were seeded onto 12-well plates and cotransfected
with firefly luciferase reporter fused to the TRIM30α
promoter (100 ng) and either an empty vector or a vector
expressing HMGB1, SiC, or SiHMGB1. At 3 days after
transfection, the lysates were analyzed using luciferase
reporter assays (Promega) according to the manu-
facturer’s protocol.
Immunofluorescence
Immunofluorescence analysis was performed as pre-
viously described14.
Cell counting
Trypan blue solution (0.4%) was added to the cell sus-
pension, and samples were incubated for 5 min at room
temperature. Cells without staining were counted using a
hemocytometer under a microscope as viable cells19.
Mouse experiment
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee (IRB no. 2019-
0242). Briefly, 7- to 8-week-old female C57BL/6 mice
were housed in a specific pathogen-free facility and were
used for allograft tumor experiments. To generate tumors,
1 × 106 B16-F10 cells suspended in 100 μL PBS were
injected into the dorsal subcutaneous area of mice, and
tumor masses were successfully formed after implanta-
tion. For tumor irradiation (IR) experiments, IR was
performed using an X-RAD 320 system (Precision X-Ray
Inc., North Branford, CT, USA). The mice were irradiated
with a single dose of 10 Gy X-ray. Three hours after the
end of the last fraction, the mice were euthanized using
CO2, and the tumor masses were extracted for subsequent
experiments. For the Dox treatment experiment, mice
were administered a single intraperitoneal injection of
Dox (9 mg/kg body weight) after tumor formation, and
tumors were collected 3 or 8 days later.
Isolation and culture of BMDMs
To generate BMDMs, bone marrow cells were collected
from Trim30+/+ and Trim30−/− mice by flushing with
Dulbecco’s PBS. BMDMs were differentiated for 7 days in
Dulbecco’s modified Eagle’s medium supplemented with
20% fetal bovine serum, 1% penicillin–streptomycin,
50 U/mL penicillin, and granulocyte macrophage-colony-
stimulating factor20.
Statistical analysis
Differences among various experimental groups were
evaluated by analysis of variance for multiple comparisons
using GraphPad Prism 5 software (GraphPad Software,
Inc., La Jolla, CA, USA). Results with P values of less than
0.05 were considered statistically significant.
Results
STING-induced senescence via p21
Recent studies have shown that STING is involved in
cellular senescence4,6. In the present study, the effects of
STING overexpression in B16-F10 cells resulted in
senescence (Fig. S1A–C), which was demonstrated by
various senescence markers, such as p21, γ-H2AX, his-
tone 3 lysine 9 trimethylation (H3K9me3) (Fig. S1A).
Furthermore, it was selectively dependent on p21 in a
dose- and time-dependent manner, but not on p16 among
the CDK inhibitors (Fig. S1B, C). And this effect on
senescence was exacerbated in the presence of genotoxic
agent doxorubicin (Dox), such as cell size, SA-β-GAL
positivity, suppression of cell growth, and increased
H3K9me3 expression were observed (Fig. 1A–F). When
we evaluated the role of STING in senescence in J774
mouse macrophage cell line, we found that Dox treatment
increased cell size and SA-β-GAL positivity and that
STING knockdown significantly blocked these effects
(Fig. 1G–I). In addition, cell numbers were significantly
increased when STING was silenced (Fig. 1J), and STING-
knockdown cells showed decreased p21 expression
induced by Dox treatment (Fig. 1K). Taken together, these
results indicated that STING caused senescence in cancer
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Fig. 1 STING-induced senescence. A–C B16-F10 cells were transfected with empty vector (C) or STING plasmid 24 h prior to Dox treatment for
3 days. Cells were photographed (A), SA-β-GAL-positive cells (B) were counted (C). B16-F10 cells were transfected with various concentrations of
empty vector (EV) or STING plasmid prior to Dox treatment, and relative cell numbers (D) and western blots for p21 (E). B16-F10 cells were transfected
with Si C or STING prior to 24 h to Dox treatment and Histone 3 lysine 9 trimethylation (H3K9me3) expression was assessed on day 3 (F). G–K J774
cells were transfected with 100 nM of Si C (control) or Si STING 24 h prior to treatment with 100 ng/ml Dox. On day 3 after Dox treatment, cells were
photographed (G), and SA-β-GAL-positive cells (H) were counted (I). Relative cell numbers were then quantified (J), and western blotting was
performed (K). Quantitative data are represented as mean ± S.D., *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, n= 3 independent trials Scale bars, 50 μm.
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cells and macrophages by regulating the CDK inhibitor
p21, which can be differentiated from previous reports
where STING induces senescence via senescence-
associated secretory phenotype (SASP)21.
HMGB1-modulated STING expression during senescence
Recently, we reported that HMGB1 orchestrated
senescence via p21 under the genotoxic stresses in various
cancer cell lines14. Thus, we aimed to investigate whether
HMGB1 interacted with STING to regulate senescence.
Accordingly, we evaluated the effects of HMGB1 on
STING-induced senescence. First, we employed B16-F10
cells to assess the role of HMGB1 in STING expression
followed by Dox treatment. Strikingly, knockdown of
HMGB1 significantly reduced STING and p21 expression
levels, whereas the expression of cGAS, the upstream
component of STING in intracellular DNA sensing, was
not changed (Figs. 2A, S2A, B), suggesting that STING
and p21 may be specific targets of HMGB1. Similar results
for STING expression were observed in J774 and
HEK293T cells following HMGB1 knockdown (Fig. 2B,
C), and other senescence markers, such as p21 and γ-
H2AX were dependent on HMGB1. Overexpression of
HMGB1 increased STING expression (Fig. 2D). These
results showed that STING was specifically regulated by
HMGB1.
Notably, STING expression was completely dependent
on HMGB1, as demonstrated in a comparison of HMGB1
wild-type (WT) vs. knockout (KO) MEFs (Fig. 2E). To
elucidate whether STING was sufficient to induce
senescence without HMGB1, we overexpressed STING in
HMGB1-KO MEFs and examined morphological changes
and cell numbers. STING overexpression resulted in a
senescence-like morphology (Fig. 2F) and reduced cell
numbers, potentially because of the induction of senes-
cence (Fig. 2G).
Because anticancer drug treatment is known to induce
senescence in cancer cells1,2, we then generated mela-
noma tumor models in mice and treated the mice with
Dox (Fig. 2H). Dox-treated tumors were positive for SA-
β-GAL staining (Fig. 2I). Indeed, the levels of STING and
p21 from tumors were correlated with those of HMGB1
following treatment with Dox (Fig. 2J). Taken together,
these findings showed that HMGB1 selectively regulated
STING expression, which was indispensable for the
induction of senescence following Dox treatment, but not
upstream or downstream molecule of canonical cGAS/
STING factors.
TRIM30α targeting induced senescence via STING
TRIM30α, an E3 ligase of the TRIM family in mice22, is
responsible for STING degradation23. Therefore, we next
investigated whether TRIM30α affected STING regula-
tion in senescence, although little has been known of the
role of TRIM30α in senescence. Because mouse mela-
noma B16 cells could not enter senescence following Dox
treatment14, presumably due to the lack of sufficient
STING expression, we knocked down TRIM30α and then
treated cells with Dox to protect STING from degrada-
tion. Interestingly, TRIM30α knockdown alone forced
cells to enter a senescent state, as observed by morpho-
logical changes (Fig. 3A), and promoted senescence fol-
lowing Dox treatment by SA-β-GAL-positive morphology
and cell numbers (Fig. 3B, C). In fact, STING expression
was increased in a Si TRIM30α concentration-dependent
manner, which was accompanied by increased expression
of the CDK inhibitors p21 and p27, but not p16 or p53
(Fig. 3D).
Next, we established a tumor model generated by
implanting B16-F10 melanoma cells into C57BL/6 mice
and treated the tumor regions with IR. Indeed, although
STING and p21 were significantly upregulated in IR-
treated tumors, TRIM30α expression showed the opposite
trend (Fig. 3E, F). We also hired J774 cells to examine
whether these phenomena were observed in mouse
macrophage cells as well (Fig. S3A–E). When J774 cells
were treated with Si TRIM30α followed by Dox,
TRIM30α knockdown enhanced the effects of Dox on the
senescence phenotype, including morphological changes
(Fig. S3A), decreased cell numbers (Fig. S3B), increased
SA-β-GAL-positive cell numbers (Fig. S3C, D), and
STING upregulation (Fig. S3E). Finally, we expended
these experiments to TRIM30α-KO mouse bone marrow-
derived macrophages (BMDMs) to verify the function of
TRIM30α in senescence (Fig. 3G). Indeed, the effects of
Dox treatment were enhanced in TRIM30α-KO mouse
BMDMs as shown in the senescence phenotype as
demonstrated by increased cell size (Fig. 3H), SA-β-GAL
positivity (Fig. 3I, J), and STING, p21, and γ-H2AX
expression (Fig. 3K). Taken together, these findings sup-
ported that TRIM30α targeting was critical for inducing
senescence by preventing STING degradation.
HMGB1-modulated TRIM30α expression to induce
senescence
Due to the effects of TRIM30α on STING-dependent
suppression of senescence, we investigated the role of
TRIM30α in HMGB1-mediated senescence. Because
STING was positively regulated by HMGB1 (Fig. 2), we
hypothesized that TRIM30α may be negatively modulated
by HMGB1 in senescence. First, we treated HMGB1-WT
and -KO MEFs with Dox and then assessed TRIM30α
expression. Interestingly, TRIM30α protein expression
was markedly reduced in WT MEFs but was upregulated
in KO MEFs following Dox treatment; the opposite
expression pattern was observed for p21 (Fig. 4A).
Changes in TRIM30α mRNA expression were consistent
with changes in protein expression (Fig. 4B). These
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Fig. 2 HMGB1-modulated STING during senescence. B16-F10 cells were transfected with 100 nM Si C or Si HMGB1 24 h prior to treatment with
100 ng/mL Dox, and western blotting was performed on day 3 after Dox treatment (A). J774 and HEK293T cells were transfected with 100 nM Si HMGB1
24 h prior to treatment with 100 ng/mL Dox, and western blotting was performed on day 3 after Dox treatment (B, C). B16-F10 cells were transfected with
HMGB1 plasmid prior to treatment with 100 ng/mL Dox. Western blotting was then performed on day 3 after Dox treatment (D). HMGB1-WT vs. -KO MEFs
were treated with Dox, and western blotting was performed (E). HMGB1-KO MEFs were transfected with STING plasmid 24 h prior to Dox treatment, then
morphological changes (F) and relative cell number were assessed on day 3 after Dox treatment (G). Tumors were generated by the implantation of B16-F10
cells into C57BL/6 mice. Mice were then injected with 9mg Dox/kg body weight on day 10. Tumors were collected on days 0, 3, and 8 after Dox treatment
(H), and tumors were stained with SA-β-GAL staining solution on day 8 after Dox treatment (I), following which western blotting was performed (J).
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Fig. 3 TRIM30α targeting induced senescence via STING. A–C B16 cells were transfected with Si C or Si TRIM30α 24 h prior to Dox treatment for
3 days. Cells were photographed (A), and SA-β-GAL-positive cells (B) were counted (C). B16 Cells were transfected with various concentrations of Si
TRIM30α, and western blotting was performed on day 3 after Dox treatment (D). E, F Tumors were generated by implantation of B16-F10 cells
into mice. On day 14 after implantation, tumors were exposed to IR. Three hours later, tumors were harvested and analyzed by western blotting.
G–K TRIM30α WT and KO mouse BMDMs were employed for analyzing the effects of TRIM30 on senescence. Real-time PCR of TRIM30α was
performed with TRIM30α-WT and -KO BMDMs (G). TRIM30α-WT and -KO BMDMs were treated with 100 ng/mL Dox, and morphological changes
(H: left, enlarged images: right), images (I), and counts (J) of SA-β-GAL-positive cells were evaluated on day 3 after treatment. Western blotting was
performed at the indicated times after treatment with 100 ng/mL Dox (K).
Lee et al. Cell Death Discovery            (2021) 7:28 Page 7 of 12
Official journal of the Cell Death Differentiation Association
Fig. 4 HMGB1-modulated TRIM30α to induce senescence. HMGB1-WT and -KO MEFs were treated with 100 ng/ml Dox for 3 days, then western
blotting (A) and qPCR (B) were performed to assess TRIM30α expression. Cells were transfected with Si C or Si HMGB1 24 h prior to Dox treatment to B16-
F10 cells for 3 days, and immunoprecipitation was performed with anti-HMGB1 antibodies. PCR was carried out using TRIM30α promoter-specific primers
for ChIP assays (C), and the binding level was quantified (D). TRIM30α promoter activity was measured by luciferase assay at day 3 after Dox treatment (E).
Cells were transfected with Si HMGB1 in a concentration-dependent manner for 2 days, and western blotting was performed (F). Cells were transfected
with HMGB1 plasmid (G) or Si HMGB1 (H) for 2 days, and western blotting was performed. HMGB1-KO MEFs were transfected with 100 nM Si C or Si
TRIM30α for 3 days. Morphological changes were photographed (I), protein expression was evaluated by western blotting (J), and mRNA expression was
estimated by qPCR (K). Quantitative data are represented as mean ± S.D., *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, n= 3 independent trials Scale bars, 50 μm.
Lee et al. Cell Death Discovery            (2021) 7:28 Page 8 of 12
Official journal of the Cell Death Differentiation Association
findings suggested that the high expression of TRIM30α
was responsible for blocking the entry of KO MEFs into a
senescent state by Dox treatment. For further investigat-
ing the effects of HMGB1 on TRIM30α, we performed
ChIP assays, the results of which showed that HMGB1
bound to the promoter region of TRIM30α; the binding
affinity was much higher in Dox-treated conditions but
decreased following silencing of HMGB1 (Fig. 4C, D). In
addition, TRIM30α promoter activity was inversely cor-
related with HMGB1 expression in MEFs (Fig. 4E).
Similarly, TRIM30α protein expression showed an inverse
correlation with HMGB1 expression in an HMGB1-
silencing dose-dependent manner in B16-F10 cells
(Fig. 4F), and these findings were further confirmed by the
upregulation or downregulation of HMGB1 (Fig. 4G, H).
Furthermore, these were also supported in HMGB1-WT
and -KO MEFs (Fig. S4).
Next, we assessed the effects of TRIM30α knockdown
in KO MEFs (Fig. 4I–K). Si TRIM30α transfection alone
and Si TRIM30α transfection plus Dox treatment resulted
in a senescence-like morphology in cells (Fig. 4I). In
addition, TRIM30α depletion increased STING and p21
protein expression (Fig. 4J) and enhanced the mRNA
levels of senescence markers, including IL-6, IL-8, and
p21, in KO cells (Fig. 4K). Collectively, these findings
suggested that HMGB1 controlled TRIM30α expression
to maintain STING for inducing senescence.
STAT6-regulated HMGB-mediated senescence
STAT6 acts downstream of STING as a transcription
factor of p21. STING recruits STAT6 to the ER, and TBK
then induces STAT6 phosphorylation, resulting in
translocation of STAT6 into the nucleus and facilitating
the induction of target genes24. In addition, in human
breast cancer cells, STAT6 functions in G1/S cell cycle
progression, and the growth-inhibitory effects of STAT6
are mediated by induction of the G1 CDK inhibitors
p21Cip1/WAF1 (p21) and p27Kip1 (p27)25. As expected,
phospho-STAT6 levels were dramatically increased along
with STING, p21, and HMGB1 expression following Dox
treatment at early time points (Fig. 5A); this effect could
be significantly blocked by STING silencing (Fig. 5B).
However, phospho-IRF3, another canonical mediator of
STING signaling, was not significantly altered by Dox
and STING silencing (Fig. 5A–C). In addition, p21 pro-
tein and SASPs IL-6 and IL-8 mRNA expression levels
Fig. 5 STAT6-mediated HMGB1-dependent senescence. B16-F10 cells were treated with Dox in a time-dependent manner, and western blotting
was performed with the indicated antibodies (A). B16-F10 cells were transfected with Si C or Si STING 24 h prior to Dox treatment for indicated times,
and western blotting was performed (B). Phospho-IRF3 expression levels were assessed at the indicated times (C). B16-F10 cells were transfected with
Si STAT6 24 h prior to Dox treatment for the indicated times, and western blots were assessed on day 3 after Dox treatment (D). Relative mRNA
expression levels of IL-6 and IL-8 were evaluated on day 3 after Si STAT6 transfection (E). Quantitative data are represented as mean ± S.D., *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001, n= 3 independent trials Scale bars, 50 μm.
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were downregulated by STAT6 silencing (Fig. 5D, E).
Taken together, these findings indicated that STAT6 may
be a specific target of STING in HMGB1-mediated
senescence. The proposed mechanism is presented in
Fig. 6.
Discussion
Senescence has emerged as an alternative anticancer
mechanism to apoptosis in chemotherapy and IR treat-
ment26,27. HMGB1 is involved in various diseases, includ-
ing cancer and senescence14,16,28. In our previous study, we
identified HMGB1 as a critical determinant of cancer cell
fate. Particularly, cancer cells underwent senescence
selectively rather than apoptosis depending on HMGB1
expression. HMGB1 induces senescence via the CDK
inhibitor p21 in the context of genotoxic stresses, such as
Dox, camptothecin, and IR, and this mechanism could be
applicable to drug-resistant cancer cells therapy14.
STING positively regulates senescence via the cGAS/
STING pathway4,6. In addition, STING can act indepen-
dently of cGAS29–31. Senescence orchestrated by the
cGAS/STING pathway occurs through the SASP rather
than the canonical senescence pathway, i.e., the p53/p21
or p16INK4a/Rb pathway21. Similarly, HMGB1 and STING
have separate roles in senescence induced by various sti-
muli, including chemotherapeutic agents; however, no
studies have examined whether these two proteins inter-
act during senescence. Therefore, in this study, we eval-
uated the roles and mechanisms of STING in HMGB1-
mediated senescence, using B16-F10 mouse melanoma
cells, which were reported to undergo senescence through
a mechanism involving HMGB1/p21 in the presence of
genotoxic stress14, and various cell lines including MEFs
and macrophages.
In our previous study, we demonstrated that HMGB1 is
indispensable for inducing senescence. In the present study,
we found that STING, but not cGAS, was regulated by
HMGB1 to induce senescence. Interestingly, STING selec-
tively regulated p21, but not other CDK inhibitors, such as
p16, to cause cell cycle arrest in senescence. Furthermore,
among known STING downstream signals, STAT6 was
selectively activated to induce p21 in our study24,25,32.
Most TRIM family proteins have E3 ubiquitin ligase
activities and function in protein quality control, innate
immunity, apoptosis, autophagy, carcinogenesis, intracel-
lular signaling, and development22. However, the role of
TRIM30, specifically TRIM30α in senescence is still
unclear. TRIM30α is a negative regulator of STING23.
Notably, in this study, we found that TRIM30α sup-
pressed STING expression to prevent senescence and that
TRIM30α silencing upregulated STING and p21, which
were required for induction of senescence. In addition,
TRIM30α was significantly downregulated in senescent
WT MEFs but was upregulated in HMGB1-KO MEFs
treated with Dox. In our study, we showed that HMGB1
negatively regulated TRIM30α in senescent WT MEFs
induced by Dox, which contributed to senescence via
STING and p21 upregulation. Therefore, we concluded
that HMGB1 suppressed TRIM30α transcription by
binding to its promoter region, and this effect was blocked
by HMGB1 silencing. Thus, our findings highlighted the
involvement of TRIM30α in the HMGB1/STING-medi-
ated senescence pathway.
To confirm our findings in vivo, we established B16-F10
cell-derived tumors in mice and evaluated the effects of
Fig. 6 Proposed mechanism of HMGB1-mediated senescence
induced by genotoxic stress. The dotted box shows our key
findings from the current study.
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Dox and IR on these tumors. Notably, Dox- and IR-treated
tumors showed significant upregulation of STING and p21
in the presence of HMGB1, whereas TRIM30α was
downregulated; these findings strongly supported our
hypothesis. However, additional studies are required to
further elucidate the function of the HMGB1/STING axis
in other pathologies.
Cellular senescence can be detected in immune cells.
Immunosenescence is a slightly different process from
cellular senescence. Immunosenescence is a cellular
hypoproliferation response to mitogenic or antigen sti-
mulation and is often observed in aging immune cells.
Although the molecular determinants of immunosenes-
cence have not been very well described, similarities with
senescence in nonimmune cells are found. For example,
the immunosenescence of T cells is regulated by p16INK4A
and p21CIP1 33,34. In our study, J774 mouse macrophages
also shared premature senescence mechanisms of cancer
cells induced by a chemotherapeutic agent.
In summary, our findings supported that senescence may
be an alternative anticancer mechanism and that
HMGB1 selectively functioned via a pathway involving
STING/STAT6/p21 to induce senescence. This pathway
involved suppression of TRIM30α expression by HMGB1
to promote STING-mediated senescence in the context of
genotoxic stress (Fig. 6). To the best of our knowledge, this
is the first study to report a link between HMGB1 and
STING in senescence. Furthermore, although most studies
on STING have shown that STING modulates senescence
via the canonical cGAS/STING pathway, in this study, we
demonstrated an unconventional mechanism of STING-
mediated senescence, independent of cGAS, in cancer cells.
Our findings could contribute to cancer prevention via
modulation of the HMGB1/TRIM30α/STING pathway to
suppress tumor cell growth by inducing senescence. Further
studies are needed to investigate whether these mechanisms
can be applied to other types of cancer cells and tissues.
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